Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Surapol Issaragrisil, MD, Richard E Clark, Josy Reiffers, MD, Franck E. Nicolini, MD, PhD, Ricardo Pasquini, Matt Kalaycio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Charisse Kemp, Xiaolin Fan, PhD, Roger J. Waltzman, MD, Giuseppe Saglio, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 1676.

https://doi.org/10.1182/blood.V120.21.1676.1676

Published: 2012

Journal Articles

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Jennifer L Beaumont, MS, Matthew Magestro, John Coombs, PharmD, MBA, Xiaolin Fan, PhD, Charisse Kemp, Roger J. Waltzman, MD

Blood (2012) 120 (21): 3166.

https://doi.org/10.1182/blood.V120.21.3166.3166

Published: 2012

Journal Articles

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Xiaolei Zhou, Catherine Copley-Merriman, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francisco Cervantes, MD, PhD, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2011) 118 (21): 795.

https://doi.org/10.1182/blood.V118.21.795.795

Published: 2011

Journal Articles

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Heinz Gisslinger, MD, Dietger Niederwieser, MD, Francesco Passamonti, MD, Roger J. Waltzman, MD, Norbert Hollaender, PhD, Deborah S. Hunter, PhD, Richard S. Levy, MD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2011) 118 (21): 279.

https://doi.org/10.1182/blood.V118.21.279.279

Published: 2011

Journal Articles

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Ruben A. Mesa, MD, Srdan Verstovsek, MD, PhD, Francisco Cervantes, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Nicolas Martin, MS, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2011) 118 (21): 1753.

https://doi.org/10.1182/blood.V118.21.1753.1753

Published: 2011

Journal Articles

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P Hughes, MD, Andreas Hochhaus, MD, Susan Branford, PhD, Martin C Müller, MD, Letizia Foroni, MD, PhD, FRCPath, Brian J. Druker, MD, François Guilhot, MD, Richard A. Larson, MD, Stephen G O’Brien, MD, PhD, Roger J. Waltzman, MD, Manisha Mone, PhD, Elisabeth Wehrle, PhD, Jerald P. Radich, MD, John M. Goldman, MD

Blood (2008) 112 (11): 334.

https://doi.org/10.1182/blood.V112.11.334.334

Published: 2008

Journal Articles

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy.

Roger J. Waltzman, MD, Patricia Braly, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4228.

https://doi.org/10.1182/blood.V104.11.4228.4228

Published: 2004

NARROW

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only